Schmidt R, Altschuler S
Angiology. 1979 Nov;30(11):744-9. doi: 10.1177/000331977903001103.
This study evaluated the effectivness of oral bronchodilator therapy using theophylline in patients with nonreversible chronic obstructive pulmonary disease. Twelve chronic obstructive pulmonary disease patients were entered into a doubleblind crossover study using either active drug theophylline in 200 mg capsules (Elixophyllin) or placebo for 3 months, followed by 3 months of the alternate capsule. At baseline and monthly visits, data were recorded, including history, physical examination, and pulmonary function testing. Clinically, 7 of 11 patients responded favorably to theophylline, 3 were unchanged, and 1 improved on placebo. Comparison of each sign and symptom individually revealed no statistically significant differences. Pulmonary function (FEV1 and FVC) showed slight deterioration with placebo, but not with active drug therapy. These findings suggest that nonasthmatic patients may improve clinically during theophylline therapy whereas their pulmonary function may deteriorate during placebo therapy.
本研究评估了使用茶碱进行口服支气管扩张剂治疗对不可逆性慢性阻塞性肺疾病患者的有效性。12名慢性阻塞性肺疾病患者进入一项双盲交叉研究，服用200毫克胶囊装的活性药物茶碱（氨茶碱）或安慰剂，为期3个月，之后交替服用另一种胶囊3个月。在基线期和每月随访时，记录数据，包括病史、体格检查和肺功能测试。临床上，11名患者中有7名对茶碱反应良好，3名无变化，1名在服用安慰剂时病情改善。对每个体征和症状单独进行比较，未发现统计学上的显著差异。肺功能（第一秒用力呼气容积和用力肺活量）在服用安慰剂时略有恶化，但在活性药物治疗时未出现恶化。这些发现表明，非哮喘患者在茶碱治疗期间临床症状可能改善，而在安慰剂治疗期间其肺功能可能恶化。
